CAB LA and VRC07-523LS for HIV-1 Viral Suppression Maintenance

Phase 2, open-label, single-arm trial of VRC07-523LS in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of Participants Experiencing a Grade 3 or Higher Adverse Event or Premature Discontinuation Due to an AE Related To Step 2 Study Treatment at 96 weeks and Cumulative Probability of Confirmed Virologic Failure at or Prior to Step 2 Week 44. Started Dec 2019; status: completed.